(Q29619251)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

30 April 2017

1 reference

1 reference

1 reference

1 reference

ORCID Public Data File 2021

Jaroslava Barkmanova

1 reference

ORCID Public Data File 2021

language of work or name

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

30 April 2017

publication date

16 May 1998

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

30 April 2017

volume

351

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

30 April 2017

issue

9114

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

30 April 2017

page(s)

1451-67

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women

30 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Hormone receptors in primary and advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Oestrogen receptors in breast tumours: associations with age, menopausal status and epidemiological and clinical features in 735 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Radiotherapy, chemotherapy, and tamoxifen as adjuncts to surgery in early breast cancer: a summary of three randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Preliminary Results From the Cancer Research Campaign Trial Evaluating Tamoxifen Duration in Women Aged Fifty Years or Older With Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Five years of tamoxifen--or more?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. The Scottish Cancer Trials Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

Results of recent large cholesterol-lowering trials and implications for clinical management

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2897%2911423-4

7 January 2021

10.1016/S0140-6736(97)11423-4

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9605801

PubMed publication ID

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017